secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0000950170-22-024560
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences Q3 2022 net loss $1.2M; cash $6.2M, expects runway through June 2023
--------------------------------------------------------------------------------

- Net loss Q3 2022 $1.2M ($0.06/share) vs $3.0M ($0.48/share) in Q3 2021.
- Cash $6.2M at Sep 30, 2022, up from $1.3M at Dec 31, 2021; expects to fund ops through June 2023.
- Completed a $5.0M public offering.
- Licensed Vanderbilt IP for REVTx-100; positive preclinical data for REVTx-300 in acute kidney injury.
- Anticipates starting Phase 1a clinical study for REVTx-100 and REVTx-300.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000095017022024560/0000950170-22-024560-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000095017022024560/revb-20221110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024560

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer